Dual Path Platform

Chembio’s proprietary DPP® technology differs from classical lateral flow tests by operating in a manner similar to that of the sequential ELISA format which is not sensitive to the “Hook Effect”.

DPP® Technological Advantages:

  • Enhanced multiplex capability up to 8 biomarkers with results in minutes
  • Significantly increased analytical and clinical sensitivity
  • Ability to effectively resolve normal aggregation/agglutination migratory issues, a common concern in lateral flow assays with large particle analytes (e.g., bacteria)
  • Adaptable to multiple sample types such as fingerstick blood, oral fluid, venous whole blood, serum and plasma

We are looking for talented, dedicated people wishing to contribute to our common vision of enhancing the health and well being of people worldwide.